Drug Trial Radar · NCT04136756
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Jun 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Oct 7, 2019
Primary completion
Apr 24, 2023
Study completion Apr 24, 2023
Sponsor
- Lead sponsor
- Nektar TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 23, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After determination of the recommended Phase 2 dose (RP2D) of NKTR-255, NKTR-255 will be evaluated in Part 2. During the Part 2 dose expansion portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. This is a Phase 1 study to evaluate safety and tolerability of NKTR-255 alone and in combination with daratumumab or rituximab.
Conditions
- Multiple Myeloma
- Non-Hodgkin Lymphoma
- Indolent Non-Hodgkin Lymphoma
Interventions
NKTR-255Drug
NKTR-255 administered by IV infusion every 21 or 28 days to establish safety and tolerability
NKTR-255 Q21Drug
NKTR-255 administered by IV infusion every 21 days to establish safety and tolerability
RituximabDrug
Rituximab administered intravenously at specified dose on specified days
DaratumumabDrug
Daratumumab administered subcutaneously at specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 as a single agentTime frame: Through study completion, an expected average of 6 months
- Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 with daratumumab SCTime frame: Through study completion, an expected average of 1 year
- Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events of NKTR-255 with rituximabTime frame: Through study completion, an expected average of 1 year
- Evaluate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of NKTR-255 as a single agentTime frame: Through study completion, an expected average of 6 months
- Evaluate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of NKTR-255 in combination with daratumumab SCTime frame: Through study completion, an expected average of 1 year
- Evaluate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of NKTR-255 in combination with rituximabTime frame: Through study completion, an expected average of 1 year
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Western Regional Medical Center - CTCA
Goodyear, Arizona
City of Hope
Duarte, California
University of California, San Francisco
San Francisco, California
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
University of Michigan
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
Memorial Sloan Kettering Cancer Center
New York, New York
New York Medical College
Valhalla, New York
Duke University Health System
Durham, North Carolina
MD Anderson Cancer Center
Houston, Texas
Virginia Cancer Specialists
Fairfax, Virginia
University of Washington
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.